In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- FDA Clears Kyowa Kirin/Ultragenyx’s XLH Drug Burosumab
April 19, 2018
- Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
- PeptiStar’s Funding Procurement Nears 20 Billion Yen
April 19, 2018
- Former GSK Japan Chief Kanako Kikuchi Named UCB Japan President
April 19, 2018
- Pharmbio Korea Gets Rights to Shionogi’s Ospemifene
April 18, 2018
- Another Huge Seller Re-Pricing Won’t Hit Opdivo Unless 195 Billion Yen Sales Reached: Ono Chief
April 18, 2018
- Sumitomo Dainippon Reorganizes Drug Discovery Research System; Accelerating Decision-Making: Pres.
April 18, 2018
- ASKA to Set Up Plant in India under JV, Eying Operation Launch in 2020
April 18, 2018
- Novo Japan Renews Sales Record in 2017 as Tresiba, Ryzodeg Gain Ground
April 17, 2018
- AstraZeneca Aims to Join Top League in Japan as It Plans Record 7 Launches in 2018
April 17, 2018
- Tagrisso Selected for 23.7% of Japanese NSCLC Patients Whose Cancer Progressed on EGFR-TKIs: Observational Study
April 17, 2018
- Eisai Teams Up with US Academia to Develop Novel TB Drugs
April 17, 2018
- Taisho Files Taurine for Recurrence Prevention of Stroke-Like Episodes in MELAS in Japan
April 17, 2018
- Tecentriq to Provide New Option for NSCLC: Oncologists
April 16, 2018
- Asian Regenerative Medicine Associations Held 1st Symposium on Regulatory Harmonization in Tokyo
April 16, 2018
- Takeda CEO Eager to Lure More Partners to Shonan iPark, Says Diversity Is Source of Creativity
April 16, 2018
- Shonan Health Innovation Park Marks Grand Opening: Takeda
April 16, 2018
- Oncodesign Partners with Erytech to Support Preclinical Development of Anticancer Drugs
April 16, 2018
- Mylan Gets EU Rights for Fujifilm Kyowa Kirin Biologics’ Humira Biosimilar
April 12, 2018
- Chugai Drops Patent Suit over Nippon Kayaku’s Herceptin Biosimilar
April 12, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…